
    
      This is a single center, double-blind, dose-escalation, placebo-controlled clinical trial.
      Dose escalation will be proceeded according to 3+3 design in five predefined dosing groups.
      After completion of the 90mg dosing study, dose-escalation will be stopped, even though MTD
      is not be observed. A total of 28 participants is scheduled to be recruited. The whole
      follow-up period for each participant will be 3 days.
    
  